116 related articles for article (PubMed ID: 20471363)
1. In vitro and in vivo antiangiogenic activity of a novel deca-peptide derived from human tissue-type plasminogen activator kringle 2.
Su L; Xu X; Zhao H; Gu Q; Zou H
Biochem Biophys Res Commun; 2010 Jun; 396(4):1012-7. PubMed ID: 20471363
[TBL] [Abstract][Full Text] [Related]
2. DGDA, a local sequence of the kringle 2 domain, is a functional motif of the tissue-type plasminogen activator's antiangiogenic kringle domain.
Kim HK; Joe YA
Biochem Biophys Res Commun; 2010 Jan; 391(1):166-9. PubMed ID: 19903452
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of pathological corneal neovascularization by a small peptide derived from human apolipoprotein (a) Kringle V.
Wang Z; Zhao H; Ma JX; Xu X
Cornea; 2014 Apr; 33(4):405-13. PubMed ID: 24452210
[TBL] [Abstract][Full Text] [Related]
4. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis.
Ji WR; Barrientos LG; Llinás M; Gray H; Villarreal X; DeFord ME; Castellino FJ; Kramer RA; Trail PA
Biochem Biophys Res Commun; 1998 Jun; 247(2):414-9. PubMed ID: 9642142
[TBL] [Abstract][Full Text] [Related]
6. Studies on the structure-activity relationship of endostatin: synthesis of human endostatin peptides exhibiting potent antiangiogenic activities.
Chillemi F; Francescato P; Ragg E; Cattaneo MG; Pola S; Vicentini L
J Med Chem; 2003 Sep; 46(19):4165-72. PubMed ID: 12954068
[TBL] [Abstract][Full Text] [Related]
7. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
Morbidelli L; Donnini S; Chillemi F; Giachetti A; Ziche M
Clin Cancer Res; 2003 Nov; 9(14):5358-69. PubMed ID: 14614021
[TBL] [Abstract][Full Text] [Related]
8. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
9. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2.
Oh HK; Ha JM; O E; Lee BH; Lee SK; Shim BS; Hong YK; Joe YA
Cancer Res; 2007 May; 67(10):4851-9. PubMed ID: 17510415
[TBL] [Abstract][Full Text] [Related]
10. Expression of the non-glycosylated kringle domain of tissue type plasminogen activator in Pichia and its anti-endothelial cell activity.
Lee SB; Oh HK; Kim HK; Joe YA
Protein Expr Purif; 2006 Nov; 50(1):1-8. PubMed ID: 16854593
[TBL] [Abstract][Full Text] [Related]
11. The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3.
MacDonald NJ; Murad AC; Fogler WE; Lu Y; Sim BK
Biochem Biophys Res Commun; 1999 Oct; 264(2):469-77. PubMed ID: 10529387
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
[TBL] [Abstract][Full Text] [Related]
13. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic action of plasma hyaluronan binding protein in human umbilical vein endothelial cells.
Jeon JW; Song HS; Moon EJ; Park SY; Son MJ; Jung SY; Kim JT; Nam DH; Choi-Miura NH; Kim KW; Kim YJ
Int J Oncol; 2006 Jul; 29(1):209-15. PubMed ID: 16773202
[TBL] [Abstract][Full Text] [Related]
15. Disruption of interkringle disulfide bond of plasminogen kringle 1-3 changes the lysine binding capability of kringle 2, but not its antiangiogenic activity.
Lee H; Kim HK; Lee JH; You WK; Chung SI; Chang SI; Park MH; Hong YK; Joe YA
Arch Biochem Biophys; 2000 Mar; 375(2):359-63. PubMed ID: 10700393
[TBL] [Abstract][Full Text] [Related]
16. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
[TBL] [Abstract][Full Text] [Related]
17. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
Olsson AK; Johansson I; Akerud H; Einarsson B; Christofferson R; Sasaki T; Timpl R; Claesson-Welsh L
Cancer Res; 2004 Dec; 64(24):9012-7. PubMed ID: 15604266
[TBL] [Abstract][Full Text] [Related]
18. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
19. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
Jung MH; Lee SH; Ahn EM; Lee YM
Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
[TBL] [Abstract][Full Text] [Related]
20. Characterization and biological activities of recombinant human plasminogen kringle 1-3 produced in Escherichia coli.
You WK; So SH; Sohn YD; Lee H; Park DH; Chung SI; Chung KH
Protein Expr Purif; 2004 Jul; 36(1):1-10. PubMed ID: 15177278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
